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Nucleolar Localization of HIV-1 Rev Is Required, Yet
Insufficient for Production of Infectious Viral Particles
Jerlisa Ann C. Arizala,1,2 Mayumi Takahashi,1,2 John C. Burnett,1
Dominique L. Ouellet,1 Haitang Li,1 and John J. Rossi1,2
Abstract
Combination antiretroviral therapy fails in complete suppression of HIV-1 due to drug resistance and persistent
latency. Novel therapeutic intervention requires knowledge of intracellular pathways responsible for viral
replication, specifically those untargeted by antiretroviral drugs. An understudied phenomenon is the nucleolar
localization of Rev phosphoprotein, which completes nucleocytoplasmic transport of unspliced/partially spliced
HIV mRNA through multimerization with intronic cis-acting targets—the Rev-response element (RRE). Rev
contains a nucleolar localization signal (NoLS) comprising the COOH terminus of the arginine-rich motif for
accumulation within nucleoli—speculated as the interaction ground for Rev with cellular proteins mediating
mRNA-independent nuclear export and splicing. Functionality of Rev nucleolar access during HIV-1 pro-
duction and infection was investigated in the context of deletion and single-point mutations within Rev-NoLS.
Mutations induced upon Rev-NoLS are hypothesized to inactivate the HIV-1 infectious cycle. HIV-1HXB2
replication ceased with Rev mutations lacking nucleolar access due to loss or replacement of multiple arginine
residues. Rev mutations missing single arginine residues remained strictly nucleolar in pattern and participated
in proviral production, however, with reduced efficiency. Viral RNA packaging also decreased in efficiency
after expression of nucleolar-localizing mutations. These results were observed during propagation of variant
HIV-1NL4-3 containing nucleolar-localizing mutations within the viral backbone (M4, M5, and M6). Lentiviral
particles produced with Rev single-point mutations were transducible at extremely low frequency. Similarly,
HIV-1NL4-3 Rev-NoLS variants lost infectivity, unlike virulent WT (wild type) HIV-1NL4-3. HIV-1NL4-3 variants
were capable of CD4+ host entry and reverse transcription as WT HIV-1NL4-3, but lacked ability to complete a
full infectious cycle. We currently reveal that viral integration is deregulated in the presence of Rev-NoLS
mutations.
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Introduction
An underexplored area in HIV-1 research is the nu-cleolar pathway viral proteins Tat and Rev participate in
during viral proliferation.UnlikeTat,which accumulates in the
nucleus and nucleolus, Rev has mainly nucleolar subcellular
localization. Upon viral infection, HIV genomic reverse tran-
scription and proviral integration into host chromosome leads
to cellular Pol II-dependent early expression of env-derived
proteins Tat, Rev, and Nef. Tat facilitates transcription and
expression of viral genes after association with a trans-
activation response element (TAR) foundwithin 5¢LTR ofHIV
transcripts.1–4 Rev achieves nucleocytoplasmic transport of
HIVmRNAs through recognition of the Rev-response element
(RRE)4–7 ‘‘A’’ conformation within env.
The ‘‘A’’ conformation involves Rev binding sites IIB and
IA that compose the opposite legs of the ‘‘A’’ shape.8
Arginine-rich motif (ARM) of Rev monomer binds IIB with
high affinity,9–11 exposing a dimerization interface for a
second Rev monomer to bind.12 Rev monomers achieve
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multimerization throughout the RRE,13,14 mainly within the
nucleolus.15 Nuclear export of Rev-RRE RNP (ribonucleo-
protein) complex occurs through the Rev nuclear export
signal (NES) interaction with chromosomal region mainte-
nance 1 (CRM1)16,17 and GTP-bound Ran,18 leading to
accumulation of intron-containing unspliced (9 kb full-length
genome containing gag/pol) and partially spliced (4 kb
fragment containing vif, vpr, vpu, and env) HIV transcripts in
cytoplasm for viral protein expression and viral particle as-
sembly.19,20
HIV-1 transcripts were previously identified in the nucle-
olus of infected peripheral blood mononuclear cells (PBMC)
during electron microscopy and in situ hybridization with
probes complementary to gag, env, and nef.21 A nucleolar
therapeutic model was hence developed against HIV-1 pro-
duction, utilizing a hammerhead ribozyme placed within U16
small nucleolar RNA platform (U16Rz) and targeted against
conserved motifs within HIV-1 5¢LTR. U16Rz was expressed
in HeLa T4, where nucleolar specificity was observed. Upon
HIV challenge, nucleolar U16Rz strongly suppressed HIV-1
production,22 selectively cleaving unspliced and partially
spliced transcripts that traversed through the nucleolus to the
sequestered ribozyme. Similarly, modified U16Rz targeting
both U5 and gag (RzC36) significantly reduced viral pro-
duction in CEM during HIV challenge.23
The potent catalytic activity of nucleolar-specific U16Rz
against HIV RRE-containing transcripts suggests an HIV-1
nucleolar pathway facilitated through Rev nucleocyto-
plasmic activity.
The dynamic and multifunctional nucleolar proteome en-
ables ribosome subunit biosynthesis, cell cycle control, apop-
tosis, DNA replication/repair, RNP biogenesis, and stress
response within subnucleolar compartments—fibrillar cen-
ters, dense fibrillar components (DFC), and outermost
granular components (GC).24,25
Viral pathogenesis induces cellular stress, leading to
transformation in nucleolar proteomic morphology as
nucleolar-accessible viral proteins recruit replication fac-
tors.26,27 Similar to HIV-1 Rev, the following single-strand
RNA viruses express nucleolar RNA binding proteins of
diverse functionality: severe acute respiratory coronavirus
nucleocapsid (N) harbors an NES predicted in nucleocyto-
plasmic shuttling activity28; dengue virus core protein
facilitates encapsidation and potentially modulates tran-
scription29; and the Semliki Forest virus nonstructural pro-
tein (nsP2) regulates viral mRNA synthesis.30
Although nucleolar trafficking is prevalent in many viral
infectious models, the purpose of this localization pattern is
unknown. In the case of HIV-1, the nucleolus may serve as
the interaction ground for Rev with cellular proteins that
facilitate rapid mRNA nuclear export and protect HIV
mRNA from spliceosomal complexes.31
Rev subnucleolar localization within DFC and GC32 oc-
curs through a nucleolar localization signal (NoLS)
45WRERQRQ51, directly downstream of the nuclear locali-
zation sequence (NLS) 34TRQARRNRRRR44 within Rev
ARM.33,34 Rev nucleolar localization was originally dem-
onstrated to occur through amino acids 40–45 (NRRRRW)
within the Rev NLS.35 Studies by Cochrane et al. later
identified amino acid residues within 35–50 of the Rev ARM
as vital for nucleolar accumulation.34 Using site-directed
mutagenesis to alter amino acids surrounding the Rev NLS
and indirect immunofluorescence, Rev localization of mu-
tations lacking amino acids 48–51 (RQRQ) maintained nu-
cleolar accumulation in the absence of HIV production.
However, when deletions were expanded to residues
WRE, resulting in complete elimination of WRERQRQ
(amino acids 45–51), nuclear accumulation was observed.34
Although a potential Rev-NoLS was identified at amino acids
45–51 downstream of the NLS, functionality of Rev nucle-
olar mutations was not investigated in the context of HIV-1
production and infection.
To characterize Rev nucleolar function, HIV-1 production
and infection were examined in the presence of Rev nucleolar
mutations. We currently reveal that Rev nucleolar access is
necessary for the completion of the HIV-1 infectious cycle.
Nucleolar activity allows efficient HIV-1mRNA splicing and
nucleocytoplasmic transport. In the background of Rev nu-
cleolar mutations, the frequency of viral integration increases
dramatically in comparison to WT (wild type) HIV-1. Ex-
treme integration frequencies result in cell death and the ar-
rest of the HIV-1 infectious cycle. We further demonstrate
the loss of Rev interaction with B23 as a result of nucleolar
mutations, and discuss the involvement of B23 in other viral
infectious models requiring nucleolar access for infectivity.
Materials and Methods
Cell culture
HeLa cells containing stably integrated copies of a Rev-
deficient HIV-1HXB2 molecular clone (HLfB) were obtained
from the NIH AIDS Research and Reference Reagent Program
(#1300). HLfB, HeLa (#CCL-2; American Type Culture Col-
lection), CD4+ HeLa (T4), human embryonic kidney 293T
(HEK293T), and human fibrosarcoma (HT1080) were cultured
in Dulbecco’s modified Eagle’s medium (DMEM) supple-
mentedwith 10% fetal bovine serum (FBS), 2mMl-glutamine,
and 1mM sodium pyruvate at 37C within a humidified
chamber with 5% CO2. Jurkat JLTRG-R5 reporter cells (NIH
AIDS Research and Reference Reagent Program #11586) ex-
pressing CD4 receptor and CCR5/CXCR4 co-receptors and T
cell lymphoblast (CEM) were maintained in RPMI-1640 sup-
plemented with 10% FBS, 2mM l-glutamine, 1mM sodium
pyruvate, 100U/ml penicillin, and 100lg/ml streptomycin.
Site-directed mutagenesis of Rev-NoLS
CMV-driven Rev-EGFP fusion within pcDNA platform36
was a template for QuickChange II site-directed muta-
genesis (Agilent Technologies). Primer sequences were de-
signed according to mutations of interest within Rev-NoLS
(Table 1). Primer sequences in Table 1 were also used to
generate 3¢Flag-tagged Rev mutations within pcDNA3.1.
Single-point mutations and deletions were confirmed
through DNA sequencing.
Site-directed mutagenesis of pNL4-3 Rev-NoLS
The Rev-NoLS fragment (*1,200 bp) was excised from
pNL4-3 (NIH AIDS Research and Reference Reagent Pro-
gram #114) using NheI and BamHI restriction digests and
ligated into pcDNA3.1. The restriction fragment was a tem-
plate for site-directed mutagenesis using primer sets (Table 2)
designed to establish mutations of Rev-NoLS M4, M5, M6,
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and M8 specifically. Mutant-positive fragment was excised
and reintroduced into the pNL4-3 backbone.
DNA sequencing was used to confirm the presence of each
Rev-NoLS mutation and deletion. WT pNL4-3 contains
reintroduced, nonmutated Rev-NoLS restriction frag-
ment, ligated alongside single-point mutant fragments
into pNL4-3. Bacterial colony PCR screens using forward
primers specific to each Rev-NoLS mutation (Table 3) in
combination with Env reverse primer 5¢-CGAATAGCTCTA
TAAGCTGCTTGTAA-3¢ were used to amplify the follow-
ing mutant clones: pNL4-3M4; pNL4-3M5; and pNL4-3M6.
DNA sequencing was used to confirm the presence of mu-
tation cDNA fragments within pNL4-3.
Restriction digest sets—BbvCI with AhdI and DraII with
PstI—were used to analyzeWT, pNL4-3M4, and pNL4-3M8
for chromosomal rearrangement using original pNL4-3
plasmid as a control. Restriction digest sets—BbvCI with
AhdI and DraIII with PstI—were used next to analyze pNL4-
3 M5 and pNL4-3 M6. All pNL4-3 mutations chosen to
propagate viral particles were subjected to a final analysis for
chromosomal rearrangement with three restriction digest
sets—PstI and DraIII, BbvCI and AhdI, and NdeI and AhdI
(Supplementary Fig. S3A–C). Mutant plasmids matching in
digestion fragment pattern with WT pNL4-3 were used to
propagate HIV-1NL4-3 particles.
Confocal microscopy
HLfB and HeLa (1· 105 cells) were cultured onto 0.01%
poly-l-lysine-treated 8-chamber CultureSlides (Falcon).
Cells were transfected the following day with 0.5 lg Rev-
NoLS-EGFP mutations using Lipofectamine 2000 reagent
(Invitrogen). Cells were fixed 12 h later in 4% paraformal-
dehyde, permeabilized in 0.1% Triton X-100, and blocked in
10% FBS for 1 h at room temperature. B23 mouse mono-
clonal IgG1 (#sc-47725; Santa Cruz Biotechnologies) diluted
to 1:250 in 10% FBS was incubated on cells for 1 h.
Cells were washed in triplicate with 1· phosphate-buffered
saline (PBS) and subjected to 1-h incubation in Alexa Fluor
555 goat-anti-mouse IgG1 diluted to 1:100. Cells were rinsed
and stained with 4¢,6-diamino-2-phenylindole (DAPI, 1 lg/
ml; Sigma-Aldrich) for 5min. Glass cover slips were
mounted onto cells using Prolong Gold anti-fade reagent
(Invitrogen) and stored at 4C in darkness. Images were taken
with a Zeiss Upright LSM510 2-Photon Microscope at
63·magnification in oil immersion and 1.7· zoom.
Table 2. pNL4-3 Rev-NoLS Mutagenic primers
Mutation Mutagenic primer set (5¢-3¢)
M4-R46G GAAGAAGGTGGGGAGAGAGACAGAGA
CAGATCCATTCGATTAG/CTAATCGA
ATGGATCTGTCTCTGTCTCTCTCCC
CACCTTCTTC
M5-R48G GTGGAGAGAGGGACAGAGACAGATCC
ATTCGATTAGTGAAC/GTTCACTAAT
CGAATGGATCTGTCTCTGTCCCTCT
CTCCAC
M6-R50G GGAGAGAGAGACAGGGACAGATCCAT
TCGATTAGTGAAC/GTTCACTAATCG
AATGGATCTGTCCCTGTCTCTCTCTCC
M8-D50–51 GAAGGTGGAGAGAGAGACAGATCC
ATTCGATTAG/CTAATCGAAT
GGATCTGTCTCTCTCTCCACCTTC
Table 1. Mutagenic Rev-NoLS Primers Corresponding to Rev Template
Mutation Mutagenic primer set (5¢-3¢) Template
M1-D48–51 GAATAGAAGGCGCCGGTGGAGAGAGATCCATTCGATATC/
GATATCGAATGGATCTCTCTCCACCGGCGCCTTCTATTC
WT Rev
M2-R48,50G GAGAGAGGGACAGGGACAGATCCATTCGATATCTGAAC/
GTTCAGATATCGAATGGATCTGTCCCTGTCCCTCTCTC
Rev M5
M4-R46G GCGCCGGTGGGGAGAGAGACAGAGACAGATCCATTCGATATC/
GATATCGAATGGATCTGTCTCTGTCTCTCTCCCCACCGGCGC
WT Rev
M5-R48G GTGGAGAGAGGGACAGAGACAGATCCATTCGATATCTGAAC/
GTTCAGATATCGAATGGATCTGTCTCTGTCCCTCTCTCCAC
WT Rev
M6-R50G GGAGAGAGAGACAGGGACAGATCCATTCGATATCTGAAC/
GTTCAGATATCGAATGGATCTGTCCCTGTCTCTCTCTCC
WT Rev
M7-D45–51 GAATAGAAGGCGCCGGATCCATTCGATATCTGAAC/
GTTCAGATATCGAATGGATCCGGCGCCTTCTATTC
Rev M1
M8-D50–51 GCCGGTGGAGAGAGAGACAGATCCATTCGATATC/
GATATCGAATGGATCTGTCTCTCTCTCCACCGGC
WT Rev
M9-R46,48,50G GAATAGAAGGCGCCGGTGGGGAGAGGGACAGGGACAGATCCATTC/
GAATGGATCTGTCCCTGTCCCTCTCCCCACCGGCGCCTTCTATTC
Rev M2
WT, wild type.
Table 3. List of Forward Primers Used
in Mutant pNL4-3 Bacterial Colony
Polymerase Chain Reaction Screen
Mutation Mutagenic primer set (5¢-3¢)
M4-R46G GAAGGAATAGAAGAAGAAGGTGGG
M5-R48G GAATAGAAGAAGAAGGTGGAGAGAGG
M6-R50G GAAGAAGAAGGTGGAGAGAGAGACAGG
M8-D50–51 GAAGAAGGTGGAGAGAGAGACAGAT
Nucleotides bolded in black represent each single-point mutation
present within the mutated clone. Nucleotides bolded in gray
represent the region located directly downstream of the M8 RQ
deletion. List of primer sets used in mutant pNL4-3 bacterial colony
PCR screen.
PCR, polymerase chain reaction.
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HIV-1HXB2 production
HLfB cells (1 · 106 cells) were grown in six-well tissue
culture plates to 50% confluency and transfected with 5 lg of
vector plasmid containing Rev-EGFP or Rev-3¢Flag (WT and
mutations) using the CaCl2 method. Supplemented DMEM
(1ml) was replaced 5 h later. Viral-containing supernatant
was collected 48 h post-transfection and centrifuged at
1,000 rpm for 5min to remove cell debris. Viral supernatant
was quantified for p24 capsid protein using HIV-1 p24
ELISA (PerkinElmer Life Sciences, Inc.).
HIV-1HXB2 RNA packaging
Viral particles generated in the presence of Rev-NoLS
mutations were analyzed for packaged RNA using Quanti-
gene 2.0 bDNA detection (Affymetrix–Panomics Solutions),
using probe sets specific to highly conserved regions within
HIV-1 vif (#SF-10183-01; Affymetrix, Inc.).
HIV-1NL4-3 infection
HIV-1NL4-3 cDNA harboring Rev-NoLS mutations was
transfected into HEK293T (50% confluent) with CaCl2 (1 lg/
well) within 12-well culture plates. Viral supernatant was
collected 48 h later, cleared of cell debris, and quantified for
p24 production. Viral supernatant normalized to 2 ng p24 was
used to infect JLTRG-R5 precultured at 1· 106 cells per well.
HIV-1-exposed cells were washed thrice in 2· HBSS 24 h
after infection and resupplemented with RPMI media. To
assess infectivity of mutant HIV-1NL4-3 variants, cells were
collected every 5 days, stained with LIVE/DEAD aqua dead
cell stain (Life Technologies), fixed in 3.7% paraformalde-
hyde, and measured for aqua fluorescence (405 nm excita-
tion) with CyAnADP 9 Color FACS analysis. Live cells were
analyzed for HIV-1 infection through EGFP emission
(488 nm excitation).
PCR detection of total HIV and 2-LTR circle DNA
Supernatant of HIV-1NL4-3—WT and Rev-NoLS muta-
tions—was normalized to 20 ng capsid p24 for infection of
JLTRG-R5 populated at 1 · 106 cells per well of 12-well
culture plates. Infected cells were washed through suspension
in 2· HBSS, thrice, 24 h after viral exposure and replenished
with RPMI media. Cells were harvested every 5 days for
genomic DNA extraction using QIAamp DNA Mini kit
(Qiagen). Amplification of total HIV-1 and 2-LTR circle
DNA was achieved using 1 lg genomic DNA subjected to
PCR primer sets (0.5 lM in final volume) and annealing
conditions described.37
Positive control fragments were derived through PCR
amplification of genomic DNA from HIV-infected CEM
(total HIV DNA) and infected CEM treated with integrase
inhibitor 118-D-24 (2-LTR circle) (NIH AIDS Research and
Reference Reagent Program #9957, 20 lm in final volume).
Primer sets specific to b-globin gene—Forward 5¢-CCC TTG
GACCCAGAGGTT CT-3¢ and Reverse 5¢-CGAGCACTT
TCT TGC CAT GA-3¢—were used as amplification and gel
loading controls under identical annealing conditions
alongside total HIV-1 and 2-LTR circle primer sets.
Lentiviral transduction
Using CaCl2, the following HIV-1-based self-inactivating
(SIN) vector and lentiviral packaging plasmids were co-
transfected into HEK293T at 50% confluency: 15lg pHIV7/
C-GFP38; 15lg pCHGP-2; 5 lg pCMV-G; and 5lg pCMV-
Rev—WT or NoLS-mutation. Lentiviral supernatant was
collected and concentrated as previously mentioned.39 Five
hundred picograms p24 supernatant was used to transduce,
through polybrene transduction (4 ll/ml), HT1080 cells
grown to 1 · 105 cells per well in 12-well plates. Transduced
cells were collected 48 h post-transduction, fixed in 3.7%
paraformaldehyde, and EGFP reporter quantified using CyAn
ADP 9 Color FACS analysis.
Northern blot analysis of HIV-1 mRNA splicing
Total RNA from HEK293T transfected with 5 lg HIV-1
pNL4-3 (50% confluent in 10 cm culture plates),WT andRev-
NoLS variants, was collected 48 h later using RNA STAT-60
(Tel-Test, Inc.) according to the manufacturer’s instructions.
Forty micrograms total RNA was electrophoresed on 1%
agarose/formaldehyde, ethidium bromide-stained gels, and
transferred onto Hybond –N nucleic acid membrane (GE
Healthcare).
RNA membrane was ultraviolet-crosslinked and blocked
in 1· PerfectHyb Plus hybridization buffer (Sigma) for 1 h at
70C. HIV RNA was detected using PCR-amplified nef
fragment originating from nucleotide positions 8475 to
890040 of pNL4-3. Amplification was accomplished with the
following primer sets: forward primer (anneals upstream of
nef and introduces the unique restriction site BamHI
CCTAGG) 5¢-GAGACAGAGACAGATCCATTCGATTA
GTGAACGGATC-3¢ and reverse primer (anneals down-
stream of nef and introduces the unique restriction site ClaI
TAGCTA) 5¢-GCCATCGATATTGTTAGCTGCTGTATT
GCTACTTGTG-3¢.
Before overnight hybridization, nef probes were radi-
olabeled with [a-32P] dCTP using the Rediprime II DNA
labeling system (GEHealthcare). Blots were rinsed afterward
in wash buffer containing 2· saline sodium citrate (SSC) and
0.1% sodium dodecyl sulfate (SDS) for 10min, thrice, and
finally in wash buffer containing 1· SSC and 0.1% SDS for
10min. Radiolabeled RNA membrane was exposed to Bio-
Max MS film (Kodak) overnight and developed for detect-
able RNA fragments. Relative density of each spliced
fragment was analyzed using ImageJ software (http://rsbweb
.nih.gov/ij).
EGFP-Vpr infectious transfer for host cell entry
HIV-1NL4-3 cDNA (1 lgWT or Rev-NoLS mutation) were
co-expressed with 1 lg pEGFP-Vpr (NIH AIDS Research
and Reference Reagent Program #11386) in HEK293T (50%
confluent) within six-well culture plates. CaCl2 transfection
media were replaced with 1ml supplemented DMEM 5h
later. Viral supernatant was collected 48 h afterward and
quantified for p24 levels. One microgram p24 viral super-
natant was used to infect 70% confluent CEM and HeLa T4
seeded in 12-well culture plates for 1.5 h. Cells were cleared
of virus with three rinses of 1· PBS, centrifugation at
1,000 rpm, and preserved in 3.7% paraformaldehyde. EGFP
positivity was quantified using FACS.
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RT assay
Viral supernatant containing WT or mutant HIV-1NL4-3
was harvested 48 h after production in HEK293T cells. Su-
pernatant was lysed to release intraviral RT. RT activity was
measured as described in the Reverse Transcriptase Assay,
colorimetric kit (Roche).
Cre-loxP lentiviral dual reporter
HEK293T cells were grown in 10 cm tissue culture plates
to 50% confluency. SIN lentiviral backbone containing LoxP
sites flanking CFP reporter with RFP reporter directly
downstream (pBB-XCXR) was co-transfected (15 lg) with
packaging plasmids described.39 Transfection media were
replaced with 6ml supplemented DMEM and 60ll (0.6M)
butyric acid 5 h post-transfection. Lentiviral supernatant was
collected 48 h later and titrated through polybrene transduc-
tion (4 ll/ml) of HT1080 (1 · 105 cells/well in 12-well
plates).
A portion of transduced HT1080 was collected 5 days la-
ter, fixed in 4% paraformaldehyde, and CFP transduction
multiplicity of infection of one viral copy per cell established
through CyAn ADP 9 Color FACS. This HT1080-XCXR
population was propagated and sorted based on CFP posi-
tivity for stable BB-XCXR reporter cells using BD AriaII
SORP (COH Analytical Cytometry Facility).
Cre-loxP recombination reporter cells (XCXR) were
transduced with 10lg Cre-Vpr lentivirus (CVITG–Cre-Vpr-
IRES-Tat-GFP backbone) produced in HEK293T with WT
or Rev-NoLS mutations. CFP transition to RFP from lenti-
viral transduction, in addition to GFP fluorescence from in-
tegration, was assessed with BD Fortessa Cytometer (COH
Analytical Cytometry Facility) after preservation in 3.7%
paraformaldehyde 7 days post-transduction. Integrase
inhibitor-118-D-24 (20lm in final volume) and RT inhibi-
tor—AZT (NIH AIDS Research and Reference Reagent
Program #3485, 10 lm in final volume)—served as negative
controls for CVITG reverse transcription and integration.
HT1080 (-) and XCXR (-) reporter cells were used as neg-
ative controls for RFP, GFP, and CFP expression.
Quantification of integrated proviral DNA
by Alu-gag PCR
Integrated viral DNA quantification was performed using
Alu-gag PCR as described previously.41–45 Total genomic
DNA was isolated from uninfected PBMC and HIV-infected
cells using QIAamp DNA mini kit (Qiagen). The amount of
isolated human genomes in the infected samples was deter-
mined by b-globin PCR using iTaq universal probe supermix
(Bio-Rad). The PCR reactions were performed on CFX96
Real-Time PCR Detection System (Bio-Rad) for 40 cycles at
following conditions: 95C for 15 s and 60C for 30 s. The
primer sequences are as follows: b-globin FP 5¢-CCC TTG
GAC CCA GAG GTT CT-3¢ and b-globin RP 5¢-CGA GCA
CTT TCT TGC CAT GA-3¢. The genomic concentrations of
samples were calculated by using a standard curve obtained
from known dilution of PBMC DNA.
The genomic DNA samples were then diluted to 2lg/ml.
Quantification of integrated DNAwas performed by two-step
Alu-gag nested PCR. The first step reaction was performed
using OneTaq 2x Master Mix (New England Biolabs) on
C1000 Thermal Cycler (Bio-Rad) at following conditions:
95C for 30 s, 40 cycles of 95C for 15 s, 50C for 15 s, and
68C for 3.5min. The primer sequences are follows: Alu FP -
GCC TCC CAA AGT GCT GGG ATT ACA G-3¢ and gag
RP 5¢-GTT CCT GCT ATG TCA CTT CC-3¢.
The product from the first step reaction was then subjected
to the second step quantitative PCR (qPCR) to quantify in-
tegrated viral DNA. The qPCR reaction was performed on
CFX96 Real-Time PCR Detection System (Bio-Rad) using
iTaq universal probe supermix (Bio-Rad) for 40 cycles at
following conditions: 95C for 15 s and 60C for 30 s. The
primer sequences are follows: RU5 FP 5¢-TTA AGC CTC
AAT AAA GCT TGC C-3¢ and RU5 RP 5¢-GTT CGG GCG
CCA CTG CTA GA-3¢. Copy number of integrated viral
DNA was calculated using a standard curve obtained from
integration standard.41–45
Immunoprecipitation
HLfB was grown to 50% confluency in six-well culture
plates and CaCl2 transfected with 5 lg Rev-3¢Flag cDNA per
well (WT and Rev-NoLS mutations). Total protein lysates
were collected 48 h later with lysis buffer (50mM Tris-HCl
pH 8.0, 137mM NaCl, and 1% Triton-X 100) treated with
protease inhibitor cocktail (Roche). One milligram per mil-
liliter protein lysate was subjected to IP with 25 ll prerinsed
anti-Flag M2 affinity gel (Sigma-Aldrich) in lysis buffer for
2 h, rotating at 4C. Flag beads were rinsed afterward 3· in
lysis buffer and boiled at 95C for 10min in 50ll 2· sample
loading buffer (without b-mercaptoethanol). Eluates were
separated from anti-flag gel and analyzed through Western
immunoblotting.
Western immunoblot
Protein eluates were subjected to an SDS-polyacrylamide
gel electrophoresis (SDS-PAGE) 15% acrylamide gel run,
transferred onto PVDF transfer membrane (GE Healthcare),
and incubated in blocking solution (5%milk with 1·TBS and
0.1% Tween—1· TBST) for 1 h at room temperature. Mem-
branes were submerged in primary antibodies diluted with
blocking solution—B23 mouse monoclonal IgG1 (1:500, #sc-
47725; Santa Cruz Biotechnologies)—and anti-Flag M2
mouse monoclonal IgG1 (1:1,000, #F3165; Sigma-Aldrich)
overnight at 4C and rinsed 3· in 1· TBST.
Membranes were incubated in secondary goat-anti-mouse
IgG1-horseradish peroxidase (1:5,000; Santa Cruz Bio-
technology) diluted in blocking solution for 1 h at room
temperature, rinsed 3· with 1· TBST, and protein bands
developed in enhanced chemiluminescence substrate (Pierce)
for 5min. Protein chemiluminescence was detected upon
exposure to BioMax MS film (Kodak) at varying time points,
and relative density of protein signals was analyzed using
ImageJ.
Results
Rev-NoLS requires two arginine residues for strict
nucleolar access during HIV-1 production
Rev mutations lacking four amino acid residues from the
NLS C-terminal end (48RQRQ51) were previously demon-
strated to maintain nucleolar localization pattern in COS-7 cell
lines; deletion mutations that extended three residues upstream
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(45WRERQRQ51) exhibited nucleolar mislocalization.34 We
replicated these nucleolar mutations and examined locali-
zation pattern in the presence of HIV production. Rev-NoLS
mutations containing amino acid deletions or single-point
substitutions of each arginine residue within NoLS—
45WRERQRQ51—were generated and fused to enhanced
green fluorescent protein (EGFP). Rev-EGFP fusion variants
were examined for intracellular localization pattern within
Rev-deficient HIV-1HXB2 during proviral production
(HLfB, Fig. 1).
Localization pattern of Rev-EGFP fusion variants was also
examined in the absence of viral production (HeLa, Supple-
mentary Fig. S1; Supplementary Data are available online at
www.liebertpub.com/aid). Rev-NoLS maintaining two argi-
nine residues after deletion (M8-DRQ) or glycine substitution
(M4-R46G, M5-R48G, and M6-R50G) remained strictly nu-
cleolar in pattern asWTRev (Fig. 1A) during viral production.
In the absence of HIV-1, the nucleolar patterns of M4, M5,
M6, and M8 were similar, however, included subnuclear
distribution outside the nucleolus (Supplementary Fig. S1A).
FIG. 1. Localization of Rev-
NoLS mutations in the presence of
HIV-1HXB2 production. HLfB cells
stably expressing Rev-deficient
HIV-1HXB2 provirus were trans-
fected with Rev-EGFP mutations
(green), fixed, immunostained with
anti-B23 nucleolar control (red),
and treated with DAPI nuclear stain
(blue). Rev-EGFP fusion mutations
were examined for intracellular lo-
calization pattern and captured at
63· magnification, oil immersion
1.7· zoom, and represented against
10lm scale bars. (A) Similar to
WT Rev, Rev-NoLS containing
single-point mutations—M4, M5,
and M6—retained nucleolar access.
Similarly, Rev-NoLS M8 retains
nucleolar access in the presence of
two arginine residues. (B) The ab-
sence of two arginine residues within
the Rev-NoLS sequence causes nu-
clear and nucleolar dispersion (M1
and M2), nuclear distribution with
deletion of NoLS (M7), and intra-
cellular localization upon substitu-
tion of all three arginine residues
within NoLS to glycine (M9). DAPI,
4¢,6-diamino-2-phenylindole; EGFP,
enhanced green fluorescent protein;
NoLS, nucleolar localization signal;
WT, wild type.
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Rev-NoLS maintaining one arginine residue after deletion
(M1-DRQRQ) and glycine substitution (M2-R48 and 50G)
allowed nucleolar entry and caused nuclear dispersion of Rev
(Fig. 1B). Similarly, M1 and M2 localized within nuclei and
nucleoli in the absence of HIV-1 (Supplementary Fig. S1B).
Rev-NoLS missing all arginine residues through deletion
(M7-DWRERQRQ) caused nuclear dispersion during HIV-
1HXB2 production (Fig. 1B) and intracellular distribution
without HIV-1 (Supplementary Fig. S1B). Glycine substitu-
tion of all arginine residues (M9-R46, 48, and 50G) resulted
in nucleocytoplasmic distribution of Rev with HIV-1
(Fig. 1B) and nuclear localization without HIV-1 (Supple-
mentary Fig. S1B).
Functionality of Rev-NoLS mutations
in HIV-1HXB2 production and RNA packaging
Functionality of Rev-NoLS mutations in the rescue of Rev
deficiency during HIV-1HXB2 production was investigated in
HLfB, which upon expression of WT Rev generates viral
particles.46 Each Rev-EGFP NoLS variant was introduced
into HLfB cells and viral particles collected 48 h afterward.
Viral output of HIV-1 p24 capsid protein was quantified
with enzyme-linked immunosorbent assay (ELISA) anti-
gen capture assays (Fig. 2A).
Rev-NoLS mutations exhibiting non-nucleolar localiza-
tion pattern in the nucleus and cytoplasm (M7 and M9) did
not rescue viral production. Simultaneous nuclear and nu-
cleolar access were also not sufficient for the rescue of viral
production (M1 and M2).
Single-point mutations retaining strict nucleolar access
(M4, M5, and M6) rescued viral production, although with
reduced efficiency compared to WT. Rev-NoLS M8, which
contains a deletion of two amino acid residues—arginine and
glutamine (DRQ)—was strictly nucleolar, yet nonfunctional.
p24 (pg/ml) was normalized to EGFP transfection efficiency
(Fig. 2C).
Functionality of Rev-NoLS mutations was examined with-
out EGFP fusion. Rev-NoLSmutations containing a 3¢Flag tag
were expressed in HLfB and viral supernatant collected 48h
later. Viral productivity through HIV-1 p24 capsid protein was
quantified with ELISA antigen capture assays.
‰
FIG. 2. Functionality of Rev-NoLS mutations in HIV-
1HXB2 proliferation and RNA packaging. Rev-EGFP mu-
tations were expressed within HLfB cells stably expressing
Rev-deficient HIV-1HXB2 provirus. Viral supernatant was
collected 48 h later and subjected to ELISA p24 antigen
capture assays for the quantification of viral production.
Viral supernatant was also quantified for the presence of
HIV-1HXB2 RNA using colorimetric bDNA assays incor-
porating probes specific to vif. In this system, WT Rev
rescues Rev deficiency and leads to HIV-1HXB2 proviral
production (A). Rev-NoLS mutations lacking nucleolar
access (M1, M2, M7, and M9) are nonfunctional in viral
production. Rev-NoLS mutations maintaining nucleolar
localization (M4, M5, and M6) produce HIV-1HXB2; nu-
cleolar M8 does not participate in viral production. (B)
Nucleolar-localizing Rev-NoLS mutations (M4, M5, and
M6), except M8, are capable of packaging HIV-1HXB2
RNA, yet not as efficiently as WT Rev. Mutants lacking
strict nucleolar localization (M1, M2, M7, and M9) do not
participate in viral RNA packaging. (C) Transfection ef-
ficiency of each Rev-NoLS mutation was quantified using
EGFP FACS analysis and was used for the normalization
of HIV-1HXB2 production (p24, pg/ml) and HIV-1HXB2
RNA packaging (RLU). Error bars represent the standard
deviation of three biological replicates. bDNA, branched
DNA; ELISA, enzyme-linked immunosorbent assay;
FACS, fluorescent-activated cell sorting; RLU, relative
light units.
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Similar results were observed without the EGFP tag
(Supplementary Fig. S2A). EGFP fusion and the addition of
the 3¢Flag tag to Rev-NoLS mutations did not alter the
function of Rev.
Rev mutations were next tested for ability to package viral
RNA using branched DNA (bDNA) colorimetric assays and
probes specific to HIV-1 vif. Each Rev-EGFP NoLS variant
was introduced into HLfB cells and viral particles collected
48 h afterward. Intraviral RNA was detected in particles
produced with nucleolar-localizing Rev mutations (M4, M5,
and M6), however, with less efficiency than WT Rev
(Fig. 2B). Nucleolar-specific M8, in addition to all other
nuclear and cytoplasmic mutations, did not participate in
RNA packaging during HIV-1HXB2 production. Intraviral
RNA, represented as chemiluminescent relative light units,
was normalized to EGFP transfection efficiency (Fig. 2C).
Rev-NoLS mutations without EGFP fusion were exam-
ined for ability to package intraviral RNA. Rev-NoLS mu-
tations containing a 3¢Flag tag were expressed in HLfB and
viral supernatant collected 48 h later. Intravirally packaged
RNA was measured using bDNA colorimetric assays with
probes specific to vif. Similar to Rev-EGFP, only nucleolar-
localizing single-point mutations (Rev-NoLS M4, M5, and
M6), except Rev-NoLS M8, were able to package intraviral
RNA (Supplementary Fig. S2B). Rescue in RNA packaging
was not as efficient asWTRev-3¢Flag. Revmutations shown to
achieve simultaneous nuclear/nucleolar localization (Rev-
NoLSM1andM2) or cytoplasmic localization (Rev-NoLSM7
andM9) lost functionality in intraviral RNA packaging. EGFP
fusion and 3¢Flag tag addition did not alter the ability of Rev-
NoLS mutations to package intraviral RNA.
HIV-1NL4-3 harboring Rev nucleolar single-point
mutations is unable to complete a full infectious cycle
Mutations corresponding to Rev-NoLS M4, M5, M6, and
M8—all nucleolar in pattern—were induced within HIV-1NL4-3
cDNA (Supplementary Fig. S3) and used to propagate virus
from HEK293T. Viral supernatant was collected 48 h later
and quantified for p24 capsid through p24 ELISA antigen
capture assays. Single-point mutations within HIV-1NL4-3
backbone (M4, M5, and M6) did not prevent viral production
and the release of p24 (Fig. 3A). In comparison to WT HIV-
1NL4-3, viral production of Rev-NoLS mutants decreased. Su-
pernatant (20 ng p24) was subjected to bDNA assays using vif
probe specific to packaged genomic RNA. Single-point mu-
tations within HIV-1NL4-3 backbone did not prevent genomic
RNA packaging within viral particles (Fig. 3B). In comparison
to WT HIV-1NL4-3, M8NL4-3 was unable to produce virus or
package genomic RNA as efficiently as WT HIV-1NL4-3.
HIV-1NL4-3 particles harboring nucleolar mutations within
the viral backbone were examined for infectivity of CD4+
JLTRG-R5. JLTRG-R5 stably expresses LTR-EGFP, in-
ducible upon Tat production after HIV-1 infection.47,48 Viral
particles containing each of the single-point mutations—
nucleolar-localizing Rev-NoLS M4, M5, and M6—were
used to infect JLTRG-R5. HIV-1NL4-3 backbone containing
the nucleolar-localizing M8 deletion did not yield viral par-
ticles and was therefore used in this study as a negative
control along with the pcDNA negative control. JLTRG-R5
was subjected to infection with 2 ng p24 viral supernatant
containing each HIV-1NL4-3 variant and washed 24 h later
with 2· HBSS (Hank’s balanced salt solution). Infected cells
were resupplemented in RPMI media. JLTRG-R5 was col-
lected afterward at 5-day intervals postinfection.
HIV-infected cells were measured for EGFP positivity
(inducible upon Tat expression after integration) using
fluorescent-activated cell sorting (FACS) analysis. Unlike
infectious WT HIV-1NL4-3, variants of HIV-1NL4-3 harbor-
ing single-point mutations (M4, M5, and M6) lacked the
ability to replicate and produce abundant Tat for the internal
activation of LTR-EGFP. Low frequency in LTR-EGFP ac-
tivation after replication of HIV-1NL4-3 variants, unlike WT
HIV-1NL4-3, was evident up to 20 days postinfection (Fig. 3C).
During the replication peak at day 15, HIV-1NL4-3 variants
exhibited significant defects in replication compared to WT
‰
FIG. 3. HIV-1NL4-3 harboring Rev nucleolar single-point mutations are unable to complete a full infectious cycle.
Mutations corresponding to Rev-NoLS M4, M5, M6, and M8—all nucleolar in pattern—were induced within HIV-1NL4-3
cDNA and used to propagate virus. Virus was collected 48 h later and quantified using p24 ELISA antigen capture assays.
Single-point mutations within HIV-1NL4-3 backbone (M4, M5, and M6) allowed viral production to occur, however, not as
efficiently as WT HIV-1NL4-3 (A). Viral supernatant (20 ng p24) was subjected to bDNA assays using probe specific to vif of
packaged genomic RNA. Single-point mutations within HIV-1NL4-3 backbone did not prevent viral RNA packaging within
viral particles (B). HIV-1NL4-3 particles (2 ng p24 viral supernatant) harboring nucleolar mutations (M4, M5, and M6)
within the viral backbone were examined for replication and infectivity of CD4+ JLTRG-R5 at 5-day intervals postinfection.
HIV-infected cells were measured for EGFP positivity using FACS analysis. Unlike infectious WT HIV-1NL4-3, HIV-1NL4-3
variants lacked the ability to replicate up to 20 days postinfection (C). HIV-1NL4-3 variants exhibited defects in the ability to
replicate and infect JLTRG-R5 compared to WT HIV-1NL4-3, which infected 20% of the entire cell population at the day 15
infectious peak (D). HIV-1NL4-3 variants replicated and infected host cells at extremely low frequency at the 15-day time
point (N= 3 during unpaired t-tests, E). Quantification of infected JLTRG-R5 is as follows for WT versus HIV1NL4-3
variants: M4 p value = .01, M5 p value = .01, and M6 p value = .01. Ability of HIV-1NL4-3 variants to gain function into the
HIV-1 infectious cycle was monitored through p24 viral output. Viral supernatant from infected JLTRG-R5 was collected at
4-day intervals until 32 days postinfection. Unlike infectious WT HIV-1NL4-3, HIV-1NL4-3 variants lacked ability to fully
regain functionality and infectivity up to 32 days postinfection (F). This was also evident upon examination of genomic
DNA harvested from HIV-infected JLTRG-R5 (WT HIV-1NL4-3 vs. single-point variants). Genomic DNA was collected
every 5 days postinfection for 25 days and subjected to PCR amplification for detection of total HIV DNA and preintegrated
2-LTR circles. Total HIV DNA was undetectable from JLTRG-R5 infected with NL4-3 variants (M4, M5, M6, and M8),
unlike detectable total HIV DNA from WT HIV-1NL4-3 starting at day 15 (G). Preintegrated 2-LTR circles accumulated in
the presence of WT HIV-1NL4-3 infection beginning at day 15; 2-LTR circles were not detected in DNA genomic samples
from the NL4-3 variants. Gel loading controls were obtained through amplification of b-globin DNA. PCR, polymerase
chain reaction; *p < .05.
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HIV-1NL4-3, which was able to replicate and infect 20% of the
entire cell population (Fig. 3D). HIV-1NL4-3 variants infected
host cells at extremely low frequency at the 15-day time point
(Fig. 3E).
Quantification of infected JLTRG-R5 is as follows for
WTversusHIV-1NL4-3 variants:M4 p value= .01,M5 p value=
.01, and M6 p value = .01. Each column represents a sample
size of three individual infectious processes during unpaired
t-tests.
Ability of HIV-1NL4-3 variants to gain function into the
HIV-1 infectious cycle was monitored through p24 viral
output. Viral supernatant from JLTRG-R5 was collected at
4-day intervals until 32 days postinfection. Unlike infec-
tious WT HIV-1NL4-3 exhibiting active viremia, HIV-1NL4-3
variants lacked the ability to fully regain functionality and
infectivity up to 32 days postinfection (Fig. 3F).
This was also evident upon examination of genomic DNA
harvested from HIV-infected JLTRG-R5 (WT HIV-1NL4-3 vs.
single-pointvariants).GenomicDNAwascollectedevery5days
postinfection for 25 days and subjected to polymerase chain re-
action (PCR) amplification for detection of total HIV DNA and
preintegrated 2-LTR circles. Total HIV DNA was undetectable
from JLTRG-R5 infected with HIV-1NL4-3 variants (M4, M5,
M6, and M8), unlike detectable total HIV DNA from WT
HIV-1NL4-3 starting at day15 and beyond (Fig. 3G).WTHIV
DNA was undetectable up to 10 days postinfection. Simi-
larly, preintegrated 2-LTR circles were not detected in DNA
genomic samples from the HIV-1NL4-3 variants; 2-LTR cir-
cles accumulated in the presence of WT HIV-1NL4-3 infec-
tion beginning at day 15. Gel loading controls were obtained
through amplification of b-globin DNA.
Lentivirus generated with nucleolar-localizing Rev
mutations is transducible at extremely low frequency
Lentiviral backbones lacking the following genes: gag/pol,
vif, vpu, env, and nef were developed previously for safe
delivery of therapeutic genes and small interfering RNAs
inhibiting HIV-1 infection.38,39,49 Lentiviral HIV7/CMV-
GFP vector containing a GFP reporter for quantification of
transduction events (Fig. 4A) was co-expressed with pack-
aging vectors, including Rev-NoLS mutations (M4, M5, and
M6), in HEK293T. Viral supernatant was collected 48 h af-
terward and normalized to 500 pg p24 before the transduction
of HT1080 (Fig. 4B).
Rev M8, previously shown to lack function in viral pro-
duction and viral RNA packaging, was analyzed as a negative
control. Viral particles were introduced into HT1080 cells,
and transduced cells quantified 48 h later using EGFP FACS
analysis. Lentivirus packaged with Rev-NoLS mutations
exhibited significantly defective transduction below 6% in
comparison to lentivirus packaged with WT Rev, in which
40% of HT1080 were transduced (Fig. 4C, D). Each column
represents a sample size of six separate transduction events
during unpaired t-tests (Fig. 4D).
Rev single-point nucleolar mutations lead
to irregularities in HIV-1NL4-3 mRNA splicing
Nucleolar mutations of interest resulting in proviral pro-
duction (Rev-NoLSM4, M5, andM6) were examined further
to identify the step of theHIV-1 infectious cycle interrupted in
the presence of Rev-NoLS mutations. The HIV-1 mRNA
splicing machinery was initially examined, as HIV-1 mRNA
splicing isdependenton thehostmRNA-splicingmachinery to
produce three mRNA species for expression of proteins re-
quired in viral assembly and release—unspliced 9 kb mRNA,
partially spliced 4 kb mRNA, and fully spliced 2 kb mRNA.
Upon infection and viral integration into host genomes, fully
spliced viral mRNA leads to expression of Tat, Rev, and Nef.
Rev in turn achieves nucleocytoplasmic transport of RRE-
containing RNAs through affinity with CRM1, involved in an
mRNA-independent nuclear export pathway.50
Rev transports partially spliced viral mRNA to the cyto-
plasm for expression of Vif, Vpr, and Vpu accessory proteins.
Rev additionally stabilizes and transports unspliced viral
mRNA to encode Gag and Gag-/Pol-derived proteins; un-
spliced HIV mRNA serves as viral genomic RNA to be
packaged within viral particles for release and re-infection of
other hosts. It is currently unknown if HIV-1 mRNA stabi-
lization for this process involves a nucleolar pathway medi-
ated by the nucleocytoplasmic activity of Rev. Rev-NoLS
single-point mutations and deletions corresponding to
nucleolar-localizing M4, M5, M6, and M8 were induced
within the HIV-1NL4-3 backbone. HIV-1 mRNA splicing was
observed as a result of nucleolar mutations to further un-
derstand the role of the nucleolus on viral mRNA splicing.
Single-point mutations incorporating glycine in replace-
ment of arginine residues were induced within the cDNA of
HIV-1NL4-3 Rev-NoLS motif (M4, M5, and M6). Deletion of
the last two amino acids of Rev-NoLS (M8) was also gen-
erated. Expression plasmid containing HIV-1NL4-3 Rev-
NoLS mutations was transfected into HEK293T and total
RNA collected 48 h later. Total RNA (40lg) was subjected
to Northern blot analysis for the detection of HIV splice
variants (unspliced 9 kb, partially spliced 4 kb, and unspliced
2 kb) using radiolabeled probe specific to nef (Fig. 5A). Ri-
bosomal RNA loading controls (60S and 40S) were captured
before blot transfer and used as standards in densitometry of
three independent experimental blots.
Unpaired t-tests (N = 6) were used in the statistical analyses
of WT mRNA versus Rev-NoLS mutant mRNA. Relative
density of unspliced Rev-NoLS variant expression (M4NL4-3,
M5NL4-3, and M6NL4-3) reduced significantly in comparison
to unspliced WT mRNA; unspliced M8NL4-3 mRNA was
similar in expression to unspliced WT mRNA (Fig. 5B).
Partially spliced HIV-1NL4-3 mRNA of WT and Rev-NoLS
variants (M4NL4-3, M5NL4-3, M6NL4-3) was similar in relative
density, unlike abundant M8NL4-3 mRNA (Fig. 5C). Fully
spliced mRNA of M6NL4-3 and M8NL4-3 was significantly
abundant compared to fully spliced WT mRNA (Fig. 5D).
M4NL4-3 and M5NL4-3 relative densities were comparable to
fully spliced WT mRNA ratio.
Rev-NoLS HIV-1NL4-3 single-point mutant particles
are capable of host cell entry
Despite nucleolar mutations, HIV-1NL4-3 particles re-
sembled WT in the ability to replicate and package in-
traviral RNA. We next tested the ability of mutant viral
particles to achieve host cell entry, quantified through in-
traviral EGFP-Vpr infectious transfer. The direct cellular
uptake of HIV-1 virions to the CD4 surface receptor has
been observed with fluorescence microscopy by co-
packaging EGFP-Vpr fusion protein to create GFP+ HIV
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particles.51 EGFP-Vpr was later utilized to monitor virion
uptake into CD4+ and CD4- HeLa cells during HIV-1 Nef
regulation of viral entry into the host cytoplasm.52
Thus, we implemented this technique to quantify the cel-
lular uptake of GFP+ HIV-1 particles co-packaged with our
Rev-NoLS variants. HIV-1NL4-3 cDNA—WT or Rev-NoLS
variants—was co-packaged with EGFP-vpr vector to prop-
agate fluorescent viral particles. CEM and CD4+ HeLa T4
cells were subjected to infection with 1lg p24 supernatant
for 1.5 h, preserved, and quantified for EGFP positivity using
FACS analysis. Despite the nucleolar single-point mutations,
viral particles are as capable of host cell entry as WT HIV-
1NL4-3 in CEM (Supplementary Fig. S4A) and HeLa T4 cells
(Supplementary Fig. S4B). Quantification of host cells with
EGFP-Vpr-M8 NL4-3 contained fluorescent background
comparable to pcDNA (-) control.
Rev-NoLS HIV-1NL4-3 single-point mutant particles
are able to achieve reverse transcription
Mutations corresponding to Rev-NoLS M4, M5, M6, and
M8—all nucleolar in pattern—were generated within HIV-
1NL4-3 cDNA and used to propagate virus in HEK293T cul-
ture. Single-point HIV-1NL4-3 particles were normalized to
20 ng of p24 supernatant and examined intravirally for
functional reverse transcriptase (RT) using a colorimetric RT
kit. HIV-1NL4-3 variants were able to produce and package
functional RT (M4, M5, and M6), unlike M8 and pcDNA
negative controls absent in RT activity (Supplementary
Fig. S5). Colorimetric values represent DNA concentration
(ng) after release of RT from viral particles and reverse
transcription thereafter.
Cre-loxP dual fluorescent reporters indicate lentiviral
entry, reverse transcription, and integration
in the background of Rev-NoLS mutations
As another test for viral entry, reverse transcription, and
integration of virus packaged with the Rev-NoLS variants,
we designed a new system based on the ability to detect viral
entry using virus carrying EGFP-Vpr fusion protein. We
created a reporter cell line of HT1080 cells integrated with a
LoxP-mCFP-LoxP-TagRFP (HT1080-XCXR) gene cas-
sette, which would undergo an mCFP (cyan) to TagRFP
FIG. 4. Transducibility of HIV/7-C-GFP lentivirus packaged with nucleolar-localizing Rev-NoLS mutations. Lentiviral
HIV7/CMV-GFP vector was co-expressed with packaging vectors, including a-flag-tagged Rev-NoLS mutations (M4, M5,
and M6), in HEK293T (A). Supernatant containing lentivirus produced with each a-flag-tagged Rev-NoLS mutation was
collected and quantified using p24 antigen capture assays (B). Lentivirus was normalized to 500 pg p24 and used to
transduce HT1080. Transduced cells were washed and fixed 48 h later, and quantified for GFP expression using FACS
analysis. Lentivirus packaged with nucleolar Rev mutations is transducible at extremely low frequency ( p values of
M4 = .0004, M5= .0002, and M6 = .0004), unlike lentivirus produced with WT-Rev (C, D). ***p < .001.
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(red) conversion upon the delivery or expression of Cre
protein (Fig. 6A). In this new system, we wanted to test for
viral entry, reverse transcription, and transgene integration
into infected cells. Thus, we created a Cre-Vpr fusion pro-
tein that was expressed from a Tat-responsive lentiviral
vector (HIV LTR–Cre-Vpr fusion–IRES–Tat/GFP fusion or
CVITG) (Fig. 6B).
Therefore, entry of the CVITG virus carrying Cre-Vpr
fusion protein would induce a conversion from mCFP ex-
pression to TagRFP expression, while successful integration
of the CVITG virus would also lead to GFP production.
CVITG lentiviral vector was co-expressed with packaging
vectors, including a-flag-tagged Rev-NoLS mutations (M4,
M5, and M6) in HEK293T.
FIG. 5. Northern blot analysis of HIV-1NL4-3 in the presence of Rev-NoLS mutations. pNL3-4 plasmid was transfected
into HEK293T culture and total RNA collected 48 h later. Total RNA (40lg) collected during HIV-1NL4-3 propagation in
HEK293T was subjected to Northern blot analyses using radiolabeled Nef probe. The known spliced variants of HIV-1
mRNA in lane 1-WT (9 kb unspliced, 4 kb partially spliced, and 2 kb spliced) were compared to HIV-1NL4-3 variants
harboring Rev-NoLS single-point mutations (lane 2: M4NL4-3, lane 3: M5NL4-3, lane 4: M6NL4-3, lane 5: M8NL4-3, and lane
6: pcDNA) (A). rRNA 60s and 40s were used as loading controls. Unspliced, partially spliced, and fully spliced HIV-1
mRNA expression were analyzed from three Northern blotting experiments using ImageJ software. Relative density of WT
unspliced HIV-1NL4-3 mRNA was compared to HIV-1NL4-3 variants harboring single-point Rev-NoLS mutations within the
viral backbone (M4 p value = .009, M5 p value = .0003, and M6 p value = .0004) (B). Unspliced mRNA contains Gag/Pol
genes. Relative density of WT partially spliced HIV-1NL4-3 mRNA was compared to HIV-1NL4-3 Rev-NoLS variants (M8 p
value = .003) (C). Partially spliced mRNA contains env, vif, and vpr genes. Relative density comparing WT fully spliced
HIV-1NL4-3 mRNA expression was compared to HIV-1NL4-3 Rev-NoLS variants (M6 p value = .008 and M8 p value <.0001)
(D). Fully spliced mRNA contains Tat, Rev, and Nef genes. **p < .01, ***p< .001, ****p< .0001.
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Viral supernatant was collected 48 h later and quantified
using p24 ELISA antigen capture assays. Rev-NoLS muta-
tions function in CVITG lentiviral production, yet not as ef-
ficiently as WT Rev (Fig. 6C). Cre-loxP recombination
reporter cells (HT1080-XCXR) were transduced with 10lg
CVITG Cre-Vpr lentivirus produced using WT or Rev-NoLS
mutations (M4, M5, and M6). Cyan fluorescent protein
(CFP) transition to red fluorescent protein (RFP) from lenti-
viral transduction, in addition to GFP fluorescence from in-
tegration, was assessed using FACS analysis.
From these experiments, we observed that CVITG virus
co-packaged with M4, M5, and M6 Rev variants was able to
induce TagRFP expression at extremely low frequency—an
indicator of lentiviral entry (Fig. 6D, E). CVITG virus co-
packaged with M4, M5, andM6 Rev variants was also able to
induce Tat/GFP expression at extremely low frequency—an
indicator of lentiviral reverse transcription and integration
(Supplementary Fig. S6A, B) in a small fraction of cells.
Lentivirus co-packaged with Rev variant M8 did not in-
duce viral entry, reverse transcription, or integration similar
to pcDNA negative control. Control experiments using WT
Rev with RT inhibitor (azidothymidine [AZT]) and/or in-
tegrase (IN) inhibitor (118-D-24) demonstrated the func-
tionality of the system to detect either viral entry (RFP+ and
GFP- cells, Fig. 6F, G) or expression of Cre and integration
(RFP+ and GFP+ cells, Supplementary Fig. S6C, D).
Rev nucleolar mutations lead to the deregulation
of HIV-1NL4-3 integration
Supernatant of HIV-1NL4-3—WT and Rev-NoLS variants
M4, M5, and M6—was normalized to 20 ng capsid p24 for
infection of JLTRG-R5 populated at 1· 106 cells per well of
12-well tissue culture plates. Cells were harvested for geno-
mic DNA starting 6, 12, 24, and 48 h postinfection. The ge-
nomic DNA samples were diluted to 2 lg/ml and quantified
for integrated viral DNA using a two-step Alu-gag PCR de-
scribed previously.41–45 Copy number of integrated viral
DNA was calculated using a standard curve obtained from
integration standard consisting of JLTRG-R5 infected with
WT HIV-1NL4-3. Viral integration of HIV-1NL4-3 variants
(M4 and M5) occurred at extremely higher frequency than
WTHIV-1NL4-3 beginning 6 h after infection (Fig. 7). Variant
M6 exhibited similar integration copies to that of WT.
Integrated copies were detected at lower frequency starting
12 h postinfection and continued to decrease gradually until
the 48-h time point after viral infection. Supernatant of
pCDNA was used as a negative control for integration in
these studies.
Rev-NoLS single-point mutations lose interaction
with B23 during viral production
Nucleolar B23 has high affinity to Rev-NoLS and func-
tions in nucleolar localization of Rev53 and nucleocyto-
plasmic transport of Rev-bound HIV mRNAs.54 The affinity
of B23 with Rev containing single-point arginine substitu-
tions and deletion was assessed through immunoprecipitation
(IP) of Rev-3¢Flag (WT and mutations) and Western immu-
noblotting. HLFB were transfected with Rev-NoLS muta-
tions (M4, M5, M6, and M8). Protein extract for IP reaction
(1mg/ml) was collected from HLFB after 48 h of HIV-1HXB2
production. IP eluates were subjected to Western immuno-
blotting using monoclonal antibodies specific to a-Flag-Rev
(Fig. 8A–C) and B23 (Fig. 8B).
In the background of Rev single-point mutations (Rev-
NoLSM4,M5, andM6), B23 binding affinity was significantly
reduced (Fig. 8D). B23 maintained affinity with WT Rev
during HIV production. Each column represents a sample size
of three IP experiments, compared during unpaired t-tests.
Discussion
Rev-NoLS in viral production and infection
Deletion of amino acids 48–51 (RQRQ) from the C-terminal
end of the Rev-NoLS maintained nucleolar accumulation in
COS-7 culture. Deletion of the entire Rev-NoLS (amino acids
45–51, WRERQRQ) caused the intracellular dispersion of
Rev.34 In our current model, removal of amino acids 48–51
(M1-RQRQ) fromRev-EGFP resulted in the nucleolar/nuclear
accumulation of Rev duringHIV-1 production in HeLa culture
expressing Rev-deficient proviral HIV-1HXB2. Similarly, nu-
cleolar/nuclear accumulation was observed upon removal of
the entire NoLS (M7-WRERQRQ).
Differences in subcellular localization in the previous study
in comparison to this observation are attributed to the presence
of an HIV-1 production model. In the absence of viral pro-
duction in HeLa culture, removal of amino acids 48–51 (Rev-
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FIG. 6. Cre-loxP dual fluorescent reporters indicate lentiviral entry, reverse transcription, and integration in the back-
ground of Rev-NoLS mutations. An HT1080 reporter cell line was generated to test for viral entry, reverse transcription, and
transgene integration. HT1080 reporters contain a LoxP-mCFP-LoxP-TagRFP (XCXR) gene cassette, which undergoes
conversion from mCFP (cyan) to TagRFP (red) upon the viral delivery of Cre protein (A). The viral delivery system
packages Cre-Vpr fusion protein expressed from a Tat-responsive lentiviral vector (HIV LTR–Cre-Vpr fusion–IRES–Tat/
GFP fusion or CVITG) (B). CVITG lentiviral vector was co-expressed with Gag/Pol and VSV-G packaging vectors91, and
a-flag-tagged Rev-NoLS mutations (M4, M5, and M6) in HEK293T. Viral supernatant was collected 48 h later and
quantified using p24 ELISA antigen capture assays. Rev-NoLS mutations M4, M5, and M6 function in lentiviral production,
but not as efficiently as WT Rev (C). XCXR were transduced with 10lg CVITG Cre-Vpr lentivirus. CFP transition to RFP
from lentiviral transduction was assessed using FACS analysis 7 days post-transduction. CVITG lentivirus co-packaged
with M4, M5, and M6 Rev variants induced TagRFP expression at extremely low frequency; this was an indicator of
lentiviral entry (D, E). Control experiments using WT Rev with reverse transcriptase inhibitor (AZT) and/or integrase
inhibitor (118-D-24) served as negative controls for CVITG transduction, and demonstrated the functionality of the
system to detect viral entry, reverse transcription, and integration (F, G). HT1080 (-) represents an additional cell
population used as negative controls for RFP and CFP expression. XCXR (-) represents a negative control population of
reporter cells that are not transduced with CVITG lentivirus. AZT, azidothymidine; CFP, cyan fluorescent protein; RFP,
red fluorescent protein.
NUCLEOLAR HIV-1 REV FOR INFECTIOUS PARTICLES 973
974
NoLSM1-RQRQ in our study) from Rev resulted in nucleolar
accumulation, previously observed in COS-7 cells.34 Removal
of amino acids 45–51 (M7-WRERQRQ in our study) caused
nuclear dispersion, also previously observed in COS-7.
With and without HIV-1 production, Rev mutations con-
taining two arginine residues within the NoLS motif are ex-
clusively nucleolar in pattern (Rev-NoLS M4, M5, M6, and
M8) as WT Rev originally containing three arginine residues
within the NoLS motif. We currently demonstrate the de-
pendence of Rev nucleolar accumulation on the presence of
at least two arginine residues within Rev-NoLS.
Nucleolar localization of HIV-1 Rev and HTLV-1 Rex was
previously demonstrated unnecessary for accumulation of
cytoplasmic unspliced RNA when tethered to an RNA op-
erator through MS2 fusion in the absence of viral response
elements55; nucleolar trafficking was therefore believed to
occur through the high affinity of viral proteins with nu-
cleolar constituents that were described as unessential for
Rev activity.
We investigated the significance of Rev nucleolar traf-
ficking and localization in HIV production models through
the rescue of Rev-deficient HIV-1HXB2 with Rev-NoLS muta-
tions. In contrast to the previous finding, we revealed that Rev
mutations lacking nucleolar entry are nonfunctional in HIV
proliferation and viral RNA packaging (M9). Partial nuclear/
nucleolar localization did not rescue viral productivity (M1,
M2, and M7).
Mutations M1, M2, and M7 lack two arginine residues
within the Rev-NoLS seuqence, and M9 lacks three arginine
residues; this would lead to conformational changes within
FIG. 7. Rev nucleolar mutations lead to the deregulation
of HIV-1NL4-3 integration. Viral supernatant (20 ng p24
capsid) collected during the propagation of WT HIV-1NL4-3
and HIV-1NL4-3 variants M4, M5, and M6 was used to infect
JLTRG-R5. Genomic DNA was harvested from JLTRG-R5
hosts starting 6, 12, 24, and 48 h postinfection. Genomic
DNA was diluted to 2 lg/ml and quantified for integrated
viral DNA using a two-step Alu-gag PCR method. Viral
integration of HIV-1NL4-3 variants (M4 and M5) occurred at
extremely higher frequency than WT HIV-1NL4-3 beginning
6 h after infection. Variant M6 exhibited similar integration
copies to that of WT. Integrated copies began to decrease
12 h postinfection and continued to decrease gradually until
the 48-h time point. Supernatant collected from pCDNA
during viral propagation was used as a negative control for
viral integration.
FIG. 8. Affinity of nucleolar Rev-NoLS mutations to B23 during viral production. HLfB culture was transfected with
Rev-NoLS mutations and protein lysate was collected 48 h after viral proliferation. Lysates were subjected to a-Flag-Rev IP
and immunodetection against B23, and assessed through Western immunoblotting. (A) Input and IP blots were incubated
with a-Flag antibody for detection of Rev expression during viral proliferation. Input and IP blots were analyzed for B23
detection and affinity to Rev during viral proliferation (B). Relative density of Rev-NoLS mutations (C) and B23 affinity
(D) were analyzed and compared to WT Rev expression and B23 affinity ( p values of M4 = .04, M5 = .04, and M6 = .05). IP,
immunoprecipitation; *p < .05.
NUCLEOLAR HIV-1 REV FOR INFECTIOUS PARTICLES 975
the a-helical structure of Rev-NoLS and interrupt Rev/RRE
binding activity.
The nonfunctional activity of M1, M2, M7, and M9 to
rescue viral production could be attributed to the inability of
Rev mutations to bind to the RRE of HIV-1 mRNAs. Strictly
nucleolar Rev mutations functioned in viral production (M4,
M5, and M6), however, with reduced efficiency compared to
WT Rev. Nucleolar-localizing M8 contains two missing
amino acids from NoLS (Arg50 and Gln51) and resulted in
defective viral production. This insufficiency in the rescue of
viral production and viral RNA packaging, despite nucleolar
accessibility ofM8, provides evidence that HIV-1 infection is
also dependent on efficient splicing and transport of HIV-1
mRNA—both processes that take place within the nucleolus.
Substitution of arginine residues at the carboxyl terminus
of the Rev NLS to alanine (Arg46, Arg48, and Arg50) was
previously demonstrated to reduce Rev/RRE binding three-
fold.4 Our observations yielded similar results upon substi-
tution of these arginine residues to glycine. p24 capsid
expression originates from unspliced HIV-1 mRNA trans-
ported to the cytosol through Rev/RRE interactions. We
observed a decrease in p24 expression in our Rev-deficient
HIV-1HXB2 model upon viral production with the expression
of nucleolar-localizing single-point mutations (Rev-NoLS
M4, M5, and M6). In comparison to WT Rev, single-point
mutations led to a three-fold decrease in p24 protein as well
as decreases in packaged genomic RNA.
Mutation of arginine residues to a similar basic amino
acid—lysine—did not affect Rev/RRE binding.4 Arg46,
Arg48, and Arg50 at the carboxyl terminus of the Rev ARM
are moderately important for phosphate and van der Waals
interactions between Rev and RRE of the HIV-1 mRNA.5
These interactions stabilize the a-helical orientation of Rev
ARM within the RRE RNA groove. The inability of
nucleolar-localizing Rev-NoLS M8 to rescue Rev deficiency
during viral production is postulated to result from two
missing amino acids from the NoLS motif (Arg50 and Gln51).
This would lead to the destabilization of the Rev ARM and
the RRE. Rev-NoLS M8 deletions would additionally lead to a
loss in nucleolar-specific protein interactions with Rev-NoLS.
Inability to rescue viral production and genomic RNA pack-
aging despite nucleolar access reveals that Rev nucleolar lo-
calization is insufficient for the progression of the HIV-1
infectious cycle. HIV-1 infection may be able to manipulate
host cellular pathways at the subnuclear level, and nucleolar
access is too simple an explanation for Rev function. Misplaced
protein interactions from nucleolar-localizing Rev-NoLS mu-
tations (M4,M5,M6, andM8) in comparison toWTRev could
identify nucleolar pathways required for HIV-1 production.
Viral particles generated in the background of Rev-NoLS
single-point mutations are capable of transduction and in-
fection at extremely low frequency. VSVG-pseudotyped
lentivirus generated with Rev-NoLS mutations replicated,
yet lacked transducibility.
Similarly, mutations introduced into the HIV-1NL4-3 cDNA
did not hinder viral production, yet resulted in the inability of
HIV-1 variants to infect host cells.We quantified the potency of
Rev-NoLS single-point mutations on viral infection through
viral output 32 days postinfection. Mutant virus lacked the
ability to regain function and participate in the viral infectious
cycle. Unlike Rev-NoLS, single-point mutation R55Q acquired
within the HIV-1 Tat basic domain—49RKKRRQRRRAHQ60
required for TAR RNA binding,56,57 NLS,58 and NoLS59—
delayed HIV-1NL4-3 production 12 days in comparison to WT
Tat.60 Other single-point mutations R52Q, R55Q, and R57Q
did not significantly affect Tat function in the transactiva-
tion of viral genes.
Rev-NoLS in HIV-1 mRNA splicing
HIV-1 mRNA splicing involves the interplay of core
splicing signals, exonic/intronic splicing enhancers and si-
lencers, and the secondary structure of the pre-mRNA.61
Core splicing signals are composed of the following three sites
commonly found in pre-mRNA: 5¢-splice site (5¢ss); 3¢-splice
site (3¢ss); and branch point sequence (BPS). 5¢ss recruits the
splicing factor U1 snRNP, and the 3¢ss allows interaction with
another splicing factor—U2AF. BPS binds to the SF1/mBBP
branch point binding protein, later displaced by U2 snRNP
during formation of the spliceosomal complex.
5¢ss and 3¢ss are categorized in pairs throughout mam-
malian pre-mRNA and are classified as strong or weak splice
sites based on affinity with corresponding splicing factors
(5¢ss with U1 snRNA, or 3¢ss with U2AF and SF1/mBBP of
the BPS). Exon definition and bridging between 5¢ss and 3¢ss
lead to formation of an early, irreversible splicing complex (E
complex), resulting in splicing reactions.62,63 Core splicing
signals are surrounded by cis-elements that either enhance
(exonic splicing enhancers [ESEs]) or repress (exonic splic-
ing silencers [ESSs]) exon definition during alternative
splicing reactions.64,65
ESEs are sequence elements within exons that interact
with serine-arginine-rich splicing factors (SR proteins). ESSs
interact with the heterogeneous ribonuclear splicing inhibi-
tors (hnRNP) to repress exon definition. Intronic splicing
silencers (ISSs) and intronic splicing enhancers are se-
quences within introns that facilitate exon definition. The pre-
mRNA secondary structure is able to modulate alternative
splicing reactions through exposure of core splicing signals
and regulatory cis-elements.66 Accumulation of partially
spliced and unspliced viral mRNA is dependent on the
presence of the RRE, located between 5¢ss D4 and 3¢ss A7
(Supplementary Fig. S7). mRNA encoding Vif, Vpr, and Tat
is expressed at extremely low levels, indicating the infrequent
activity of 3¢ss A1, A2, and A3.67
Partially spliced 4 kb vif mRNA, a product of 5¢ss D1 to
3¢ss A1, composes 1% of incompletely spliced viral mRNA
in infected cells. VprmRNA, a product of 5¢ss D1 to 3¢ss A2,
composes 2% of total partially spliced mRNAs. Approxi-
mately half of all spliced viral mRNA is fully spliced 2 kb
mRNA, indicating frequent splicing at 3¢ss A7. Tat mRNA
composes 9% of completely spliced mRNA (two-exon Tat)
and 5% of partially spliced mRNA (one-exon Tat). Tat
mRNAs are formed through splicing activity at 5¢ss of D1,
D2, D3, or D4 to 3¢ss A3.
Transcripts leading to Vpu, Env, and Rev are abundantly
expressed, indicating the frequent use of 3¢ss A4c, A4a, A4b,
and A5. The center of HIV-1 pre-mRNA contains 3¢ss clus-
ters leading to the accumulation of fully spliced rev mRNA
(5¢ss D3 or D4 to 3¢ss of A4c, A4a, or A4b), fully spliced nef
mRNA (5¢ss D3 or D4 to 3¢ss A5), and partially spliced env/
vpumRNAs (5¢ss D2 or D3 to 3¢ss cluster). Both populations
compose 90% of completely spliced mRNA and 92% of
partially spliced mRNA.
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Alternatively, mRNA leading to expression of two-exon
Tat, Rev, and Nef utilizes 3¢ss A7. Efficient splicing activity
at A7 requires ESS, ESE, and ISS elements.68,69 Novel 5¢ss
D1A and 3¢ss A1A identified within gag/pol mRNA are
utilized at low frequency compared to other splice sites
within the HIV-1 pre-mRNA.70 The 5¢ss D1A is suggested as
a necessary feature to prevent the degradation of unspliced
viral mRNA. U1 snRNP bound to 5¢ss D1A recruits SR
proteins that may stabilize the binding of Rev to the viral
RNA, leading to the nuclear export of unspliced HIV-1 RNA.
Based on the observations of Rev mutations (M4, M5, and
M6), the inability of lentivirus to replicate and packagemRNA
may result from single-point mutational defects affecting Rev/
RRE binding and nucleocytoplasmic transport. Specifically,
Arg35 and Arg39 of Rev ARM interact with nucleotides U66,
G67, and G70 of RRE major groove; Asn40 and Arg44 interact
with U45, G46, G47, and A73, opposite the major groove.4
Arg46, Arg48, and Arg50 at the COOH terminus of Rev ARM
are suggested as being moderately important for specific
binding to achieve phosphate and van der Waals contacts in an
a-helical orientation within the RRE groove.5
In our studies, substitution of RevArg46 (M4), Arg48 (M5),
and Arg50 (M6) with glycine within proviral cDNA leads to
spliceosomal irregularities. The 9 kb mRNA of HIV-1NL4-3
variants significantly reduced in expression compared to WT
HIV-1NL4-3; Arg
50-Gln51 deletion within the M8 variant ex-
hibited abundant 4 and 2 kb mRNA than WT HIV-1NL4-3.
These findings exemplify the importance of Rev-NoLS in
RRE binding and HIV-1 mRNA transport.
We observed that Rev single-point mutations decrease the
cytoplasmic export of the 9 kb HIV-1 mRNA, thereby leading
to the decrease of p24 production, since p24 is derived from
gag/pol precursors of 9 kb mRNA.46,71 Two amino acid dele-
tions of M8 did not significantly change the levels of the 9 kb
mRNA, although disproportionately higher levels of 2 and 4 kb
mRNA splice variants were observed. Impairment of Rev in
facilitating nucleocytoplasmic transport of unspliced and par-
tially spliced transcripts could result in the accumulation of
fully spliced 2 kb transcripts, which encode Tat, Rev, and Nef
proteins. Therefore, an increase of Tat expression would acti-
vate the Tat-positive feedback loop, leading to the enhanced
transactivation of HIV gene expression and the subsequent
accumulation of 2 and 4 kb mRNAs.6,72
This is also consistent with computational models, which
predict an increase of 2, 4, and 9 kb transcripts upon inhibition
of Rev.73 The proportionality of spliced/unspliced mRNA
variants may be a prerequisite for viral production and infec-
tion. In addition, host cell protein interactions with Rev in the
nucleolus may regulate HIV mRNA transport and splicing.
Nucleolar B23 is involved in nucleocytoplasmic shuttling
of Rev-bound HIV mRNA and is well characterized in its
interactions with the NoLS of host factors—p120 growth
factor (amino acids 40–57)74 and C23 pre-rRNA processor
(amino acids 540–628)75—and retroviral proteins HTLV-1
Rex (amino acids 1–22)76 and HIV-1 Tat (amino acids 49–
57).77 Currently, we reveal that Rev-NoLS single-point mu-
tations abolished B23 interaction with Rev. This may lead to
the disruption of nucleocytoplasmic shuttling of HIV
mRNAs. We also reveal that the loss of B23 interaction with
Rev does not hinder viral production, yet diminishes viral
infectivity, suggesting that other nucleolar factors are in-
volved in viral production.
Rev-NoLS in the viral entry, reverse transcription,
and integration of HIV-1
Rev single-point mutations were demonstrated to allow the
entry of EGFP-Vpr-labeled HIV-1NL4-3 particles into host
cells. We postulated that defects in HIV-1 production in the
presence of nucleolar mutations occur postentry during re-
verse transcription and/or integration. Rev-NoLS mutants
M4NL4-3, M5NL4-3, and M6NL4-3 exhibited reduced expres-
sion of p24 capsid, RT, and packaged RNA; this would result
from the reduced expression of Gag/Pol precursors as well as
the C packaging element, all originating from 9 kb HIV
mRNA, in the presence of single-point mutations. Rev mu-
tant M8NL4-3 produced p24 capsid, RT, and packaged RNA at
extremely low quantities in comparison to HIV-1 mutants
M4NL4-3, M5NL4-3, and M6NL4-3; this would result from the
constant splicing of the 9 kb mRNA and accumulation of 4
and 2 kb mRNA fragments in the presence of nonfunctional
Rev M8.
Nullbasic, a transdominant negative mutation of Tat,
contains glycine/alanine substitutions of the Tat basic do-
main (amino acids 49–57). Nullbasic was demonstrated to
reduce HIV-1 infection of MAGI, Jurkat, and human primary
CD4+ T cells during reverse transcription.78,79 The mecha-
nism by which Nullbasic interrupts reverse transcription is
unclear. Nullbasic Tat was further demonstrated in redistri-
bution of nucleolar Rev to cytoplasm and downregulation of
Rev-mediatedmRNA transport and expression of Gag-derived
proteins.78 Nullbasic co-expression with Rev caused disper-
sion of nucleolar CRM1, B23, and nucleolin to the nucleus.80
Absence of the Tat basic domain in Nullbasic, which in-
teracts with B23,77 would suggest alternative indirect inter-
actions between Tat and Rev besides B23. Mutation within
Rev-NoLS may in turn interrupt Tat function through this
unknown pathway; identification of host factors involved in
this mechanism would explain reverse transcription defi-
ciencies in the presence of Nullbasic Tat as well as Rev-NoLS
single-point mutations. Alternatively, nucleolar factors such as
B23 may be required within viral particles to directly facilitate
reverse transcription postentry, and reduction of cellular fac-
tors through Rev-NoLSmutations could lead to the defects and
reduction of reverse transcription.
Lentivirus generated in the background of Rev-NoLS
single-point mutations (M4, M5, and M6) transduced host
cells, however, at extremely low frequency in comparison to
WT lentivirus. Transducibility in this model is defined by the
ability of lentivirus to achieve host cell entry, reverse tran-
scription, and integration. These events are quantifiable
through reporters placed within the lentiviral backbone
(HIV7/C-GFP contains a GFP reporter to detect reverse
transcription and integration; CVITG contains GFP for de-
tection of reverse transcription and integration, and produces
Cre to induce Cre-LoxP-dependent cleavage of stably ex-
pressed LoxP-CFP-LoxP-RFP reporters for detection of
lentiviral entry in HT1080-XCXR hosts).
The inability of HIV7/C-GFP and CVITG lentivirus to
fully transduce host cells in the presence of Rev-NoLS mu-
tations reveals a deficiency during the integration step. In a
separate infectious model, deficient integration was observed
upon inability of HIV-1NL4-3 variants to integrate into
JLTRG-R5 hosts, preventing the Tat-inducible activation of
internal LTR-EGFP reporters.
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A previous study demonstrated the intracellular interaction
of HIV-1 integrase and Rev using bimolecular fluorescence
complementation and co-IP assay systems.81 Rev protein is
initially transcribed from unintegrated viral DNA at the early
stages of infection before the integration step occurs, and is
believed to have inhibitory effects on the enzymatic ac-
tivity of integrase. An HIV-1-infected cell typically contains
a limited number of integrated viral genomes per host
cell—namely one or two integration events have been ob-
served. Several integration events are documented in other
retroviruses—murine leukemia virus and Rous sarcoma
virus—suggesting different regulatory mechanisms of viral
integration in other retroviral models.
Two integrase-derived peptides (INr-1 and INr-2) were
shown to diminish the inhibitory effects of Rev on integrase
activity and stimulate multiple viral DNA integration events
during kinetics studies. These findings suggest the involve-
ment of the Rev nucleolar pathway in the regulation of len-
tiviral integration. Formation of the lens epithelium-derived
growth factor p75 (LEDGF/p75) complex with Rev was
previously observed as a crucial step in regulating viral
cDNA integration.82 Co-IP experiments revealed that an IN-
LEDGF/p75 complex is formed postinfection, which is later
replaced by Rev-LEDGF/p75 and Rev-IN complexes. Nu-
cleolar single-point mutations, namely in the background of
M4 and M5, may hinder the Rev-dependent regulation of
integrase. This would result in the high frequencies of viral
integration observed in this study.
Cellular host factors involved in the HIV-1
nucleolar pathway
Single-point mutations induced within Rev-NoLS were
expected to decrease binding affinity to other cellular host
factors facilitating Rev functionality in HIV mRNA binding
and transport. Nucleolar B23 is involved in the nucleocy-
toplasmic shuttling of Rev-bound mRNA.53,54 Rev-NoLS
single-point mutations in this model abolished B23 affinity
to Rev, indicating disruption in nucleocytoplasmic shuttling
and HIV mRNA transport. Disruption of B23 interaction with
Rev in turn does not hinder viral production, yet diminishes
ability to produce infectious viral particles. We postulate that
nucleolar factors, transport factors, and splicing factors in-
volved in B23 function further participate in the HIV-1 in-
fectious cycle.
B23-mediated transport of nucleolar viral proteins, viral
assembly, encapsidation, production, and latency is docu-
mented in other viral infectious models. B23 is characterized
in interactions with NoLS of cellular factors for nucleo-
cytoplasmic transport—p120 growth factor (amino acids
40–57)74 and C23 pre-rRNA processor (amino acids 540–
628)75—and with retroviral proteins HTLV-1 Rex (amino
acids 1–22),76 HIV-1 Tat (amino acids 49–57),77 and HIV-1
Rev (amino acids 37–47).83 Juvenile Encephalitis virus (JEV)
infection is transmitted through mosquito vectors, leading to
acute encephalitis in humans. The JEV genome encodes a
nucleolar-localizing core protein, through which amino acids
Gly42 and Pro43 interact with N-terminal region of B23
during JEV infection, resulting in transportation of viral core
protein/B23 into the nucleus.84
The single-strand RNA HBV causes cirrhosis and hepa-
tocellular carcinoma during infection. The HBV genome is
composed partially of double-stranded DNA, which encodes
a nucleolar core protein. HBV core protein associates with
nucleolin and B23 in the nucleolus85; B23 was demonstrated
in HBV assembly through interaction with the core protein N-
terminal domain. Specifically, B23 amino acids 259–294
bind the N-terminal domain of HBV core protein to allow
viral encapsidation.86
The negative-sense, single-strand RNA hepatitis D virus
(HDV) expresses HDVAg antigen in two isoforms; the small
isoform aids in RNA replication and the large isoform fa-
cilitates viral assembly. RNA replication takes place within
the nucleolus and requires B23 interaction with HDVAg.87,88
HDV infection causes an upregulation of B23, which inter-
acts mostly with the small HDVAg isoform and less with the
large HDVAg isoform. Interactions take place through the
small HDVAg NLS domain, through which B23 binds and
achieves nuclear accumulation. Upon deletion of HDV
binding site to B23, RNA replication was impaired. HDVAg
was shown to co-localize with B23 and nucleolin in the nu-
cleolus. Nucleolin was discovered to possess transcriptional
properties as a repressor,89 revealing the nucleolus as a
compartment for regulation of HDV replication.
B23 is involved in latency of the double-strand DNA
Kaposi sarcoma herpesvirus (KSHV), which leads to Ka-
posi’s sarcoma and is associated with AIDS-induced non-
Hodgkin lymphoma. KSHV latent protein—v-cyclin—with
host CDK6 kinase phosphorylates B23 at Thr199, facilitating
B23 interaction with latency-associated nuclear antigen.90
The latency-associated nuclear antigen acts to prevent viral
lytic replication. Depletion of B23 leads to KSHV reactiva-
tion, revealing B23 as a regulator of KSHV latency. B23
function in the HIV production cycle is characterized in nu-
cleocytoplasmic transport activity of Tat and Rev, and it is
unknown if B23 can induce latency during HIV infection.
B23 involvement in the production, encapsidation, and as-
sembly of HIV is also unknown.
Conclusion
We currently demonstrate Rev nucleolar access a re-
quirement for HIV-1 production and pathogenesis. This lo-
calization pattern allows efficient HIV-1 mRNA splicing and
nucleocytoplasmic transport. We reveal an extra step during
the HIV-1 infectious cycle in the nucleolus through Rev
nucleocytoplasmic activity, required for production of in-
fectious viral particles. Interference with nucleolar activity
through mutation of Rev-NoLS diminishes the ability of
HIV-1 to regulate viral integration within host cells, thereby
leading to host cell death and termination of the viral infec-
tious cycle.
In summary, we find that HIV-1 utilizes a nucleolar
pathway to maintain an infectious cycle. Our findings suggest
that this understudied pathway is a novel therapeutic target
for the interference of HIV-1 infection. Nucleolar manipu-
lation could be applicable against other viral infections and
disease models requiring nucleolar access.
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